Oncology DevelopmentThe continuing advancement of candidates such as BNT122, BNT111, BNT113, BNT116, BNT211, BNT316, BNT323, and BNT327 appear to demonstrate the tangibility of BioNTech's efforts in the oncology arena.
Strong Financial PositionBioNTech's $19B balance sheet could help beat Summit to market.
Technological AdvantageBioNTech's widespread adoption of AI provides a competitive advantage.